Oral Session 3-10A MM: Clinical trials

[OS3-10A-2] Extended 5-y follow-up of ELOQUENT-2 Japanese subanalysis: elotuzumab + len/dex for multiple myeloma

Morio Matsumoto¹, Kazutaka Sunami², Kenshi Suzuki³, Kazuteru Ohashi⁴, Shinsuke Iida⁵, Shinichiro Okamoto⁶, Hiroshi Handa⁷, Kosei Matsue⁸, Suresh Shelat⁹, Oumar Sy⁹, Masafumi Miyoshi¹⁰, Masafumi Taniwaki¹¹ (1.National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan, 2.National Hospital Organization Okayama Medical Center, Okayama, Japan, 3.Japanese Red Cross Medical Center, Tokyo, Japan, 4.Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, 5.Nagoya City University Hospital, Nagoya, Japan, 6.Keio University Hospital, Tokyo, Japan, 7.Gunma University Hospital, Maebashi, Japan, 8.Kameda Medical Center, Kamogawa, Japan, 9.Bristol-Myers Squibb, Princeton, NJ, USA, 10.Bristol-Myers Squibb K.K., Tokyo, Japan, 11.University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan)